Proteologix, Inc., a biotechnology company focused on developing bispecific antibodies for immune-mediated diseases, has entered into a definitive agreement to be acquired by Johnson & Johnson for $850 million in cash, with potential for an additional milestone payment. This acquisition will provide Johnson & Johnson with a robust pipeline of differentiated bispecific antibodies with best-in-disease potential, allowing the company to rapidly develop and realize the full potential of Proteologix's lead programs in atopic dermatitis, asthma, and other significant immune-mediated diseases.